Metabolic syndrome in bipolar disorder and schizophrenia: Dietary and lifestyle factors compared to the general population

Bipolar Disorders

Volumn 16, Issue 3, 2014, Pages 277-288

  Bly, Michael J ^a   Taylor, Stephan F ^b   Dalack, Gregory ^b   Pop Busui, Rodica ^b   Burghardt, Kyle J ^a   Evans, Simon J ^b   Mcinnis, Melvin I ^b   Grove, Tyler B ^a,b   Brook, Robert D ^b   Zöllner, Sebastian K ^a,b   Ellingrod, Vicki L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotics; Bipolar disorder; Dietary intake; Metabolic syndrome; Schizophrenia

Indexed keywords

CARBOHYDRATE; CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY MASS; CALORIE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; EXERCISE; FAT INTAKE; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; COMPLICATION; DIET; HEALTH CARE PLANNING; METABOLIC DISEASES; MIDDLE AGED; NUTRITION; RISK FACTOR;

ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; DIET; FEMALE; HUMANS; LIFE STYLE; MALE; METABOLIC DISEASES; MIDDLE AGED; NUTRITION SURVEYS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84899740701     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12160     Document Type: Article

References (57)

1. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
2. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-387.
3. Davidson MH. A symposium: National Cholesterol Education Program Adult Treatment Panel III: impact and implementation of the new guidelines. Introduction. Am J Cardiol 2002; 89: 1C-2C.
4. Correll C, Frederickson A, Kane J, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008; 10: 788-797.
5. Ellingrod VL, Taylor SF, Dalack G et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 2012; 32: 261-265.
6. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008; 98: 47-54.
7. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010; 121: 193-198.
8. Belin R, Greenland P, Allison M et al. Diet quality and the risk of cardiovascular disease: the Women's Health Initiative (WHI). Am J Clin Nutr 2011; 94: 49-57.
9. Bowles D, Laughlin MH. Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease. J Appl Physiol 2011; 111: 308-310.
10. Dubbert P, Carithers T, Sumner A et al. Obesity, physical inactivity, and risk for cardiovascular disease. Am J Med Sci 2002; 324: 116-126.
11. Gade W, Schmit J, Collins M, Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci 2010; 23: 61.
12. Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3: A42.
13. Leao LS, de Moraes MM, de Carvalho GX, Koifman RJ. Nutritional interventions in metabolic syndrome: a systematic review. Arq Bras Cardiol 2011; 97: 260-265.
14. Ellingrod V, Taylor S, Brook R et al. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res 2011; 130: 20-26.
15. Langenecker SA, Saunders EF, Kade AM, Ransom MT, McInnis MG. Intermediate: cognitive phenotypes in bipolar disorder. J Affect Disord 2010; 122: 285-293.
16. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1999-2000. Available from: http://www.cdc.gov/nchs/nhanes [accessed November 2011].
17. Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624-629.
18. Nurnberger JI Jr, Blehar MC, Kaufmann CA et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849-859.
19. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255-262.
20. Rummel-Kluge C, Komossa K, Schwarz S et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233.
21. Moshfegh AJ, Rhodes DG, Baer DJ et al. The US department of agriculture automated multiple-pass method reduces bias in the collection of energy intakes. Am J Clin Nutr 2008; 88: 324-332.
22. Schatzkin A, Kipnis V, Carroll RJ et al. A comparison of a food frequency questionnaire with a 24-hour recall for use in an epidemiological cohort study: results from the biomarker-based observing protein and energy nutrition (OPEN) study. Int J Epidemiol 2003; 32: 1054-1062.
23. Kipnis V, Subar AF, Midthune D et al. Structure of dietary measurement error: results of the OPEN biomarker study. Am J Epidemiol 2003; 158: 14-21.
24. Subar AF, Kirkpatrick SI, Mittl B et al. The Automated Self-Administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators from the National Cancer Institute. J Acad Nutr Diet 2012; 112: 1134-1137.
25. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013; 47: 197-207.
26. Schakel SF. Maintaining a nutrient database in a changing marketplace: keeping pace with changing food products - a research perspective. J Food Composit Anal 2001; 14: 315-322.
27. Orrell A, Doherty P, Miles J, Lewin R. Development and validation of a very brief questionnaire measure of physical activity in adults with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2007; 14: 615-623.
28. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol 2011; 44: 203-215.
29. Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; 4: CD006627.
30. Marik P, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-372.
31. Burghardt PR, Kemmerer ES, Buck BJ et al. Dietary n-3: N-6 fatty acid ratios differentially influence hormonal signature in a rodent model of metabolic syndrome relative to healthy controls. Nutr Metab 2010; 7: 53.
32. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
33. Meyer JM, Nasrallah HA, McEvoy JP et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80: 9-18.
34. Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45-53.
35. Daumit GL, Goff DC, Meyer JM et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008; 105: 175-187.
36. Patel JK, Buckley PF, Woolson S et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
37. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 2008; 11: 679-684.
38. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012; 70: 3-21.
39. Megna JL, Schwartz TL, Siddiqui UA, Herrera Rojas M. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry 2011; 23: 131-140.
40. Wall R, Ross RP, Fitzgerald G, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010; 68: 280-289.
41. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97-107.
42. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-126.
43. McIntyre RS, Park KY, Law CW et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 2010; 24: 741-753.
44. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272.
45. Uher R, Mors O, Hauser J et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol 2011; 14: 367-375.
46. Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD. Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry 2012; 71: 136-145.
47. Misawa F, Shimizu K, Fujii Y et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry 2011; 11: 118.
48. Elderon L, Whooley MA. Depression and cardiovascular disease. Prog Cardiovasc Dis 2013; 55: 511-523.
49. Strassnig M, Singh Brar J, Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res 2005; 76: 343-351.
50. Alaimo K, McDowell MA, Briefel RR et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data 1994; 258: 1-28.
51. Henderson DC, Borba CP, Daley TB et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18: 99-105.
52. Jacka FN, Pasco JA, Mykletun A et al. Diet quality in bipolar disorder in a population-based sample of women. J Affect Disord 2011; 129: 332-337.
53. Wertz PW. Essential fatty acids and dietary stress. Toxicol Ind Health 2009; 25: 279-283.
54. Gordon-Larsen P, Popkin B. Understanding socioeconomic and racial/ethnic status disparities in diet, exercise, and weight: underlying contextual factors and pathways. J Am Diet Assoc 2011; 111: 1816-1819.
55. Isaac M, Chand P, Murthy P. Schizophrenia outcome measures in the wider international community. Br J Psychiatry Suppl 2007; 50: S71-S77.
56. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76.
57. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13.